Doxofylline Syrup Suppliers & Bulk Manufacturers
Available Forms: Oral Syrup
Available Strengths: 100 mg/5 ml, 200 mg/5 ml,
Reference Brands: Doxolin (India), Doxofyl (India/LATAM)
Category:
Respiratory Disorder
Doxofylline is a methylxanthine derivative used in chronic obstructive pulmonary disease, asthma, and bronchospasms.
Doxofylline Syrup is available in Oral Syrup
and strengths such as 100 mg/5 ml, 200 mg/5 ml,.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Doxofylline Syrup is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Doxofylline Syrup can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Doxofylline is a xanthine-derived bronchodilator used in the management of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. It works by relaxing the smooth muscles of the airways, leading to bronchodilation and improved airflow, thereby helping patients breathe more easily. Doxofylline has been widely studied and is considered to have comparable efficacy to theophylline in controlling respiratory symptoms, but with a significantly improved safety profile and fewer side effects, particularly related to the cardiovascular and central nervous systems.
This makes it a preferred alternative in many clinical settings where long-term bronchodilator therapy is required. In addition to asthma and COPD, doxofylline has shown potential benefits in the treatment of bronchiectasis, and in 2014, it received orphan drug designation from the US Food and Drug Administration (FDA) for this indication. The drug is generally well tolerated, with mild side effects such as nausea, headache, or gastrointestinal discomfort reported in some patients. It is available in various dosage forms including tablets and syrups and is widely used across global markets for effective respiratory care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing